Lumicitabine

Last updated
Lumicitabine
Lumicitabine structure.png
Clinical data
Trade names Lumicitabine
Legal status
Legal status
Identifiers
  • [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(chloromethyl)-4-fluoro-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard 100.245.433 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C18H25ClFN3O6
Molar mass 433.86 g·mol−1
3D model (JSmol)
  • CC(C)C(=O)OC[C@@]1([C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)F)OC(=O)C(C)C)CCl
  • InChI=1S/C18H25ClFN3O6/c1-9(2)15(24)27-8-18(7-19)13(28-16(25)10(3)4)12(20)14(29-18)23-6-5-11(21)22-17(23)26/h5-6,9-10,12-14H,7-8H2,1-4H3,(H2,21,22,26)/t12-,13+,14-,18-/m1/s1
  • Key:MJVKYGMNSQJLIN-KYZVSKTDSA-N

Lumicitabine (ALS-8176) is an antiviral drug which was developed as a treatment for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). It acts as an RNA polymerase inhibitor. [1] While it showed promise in early clinical trials, [2] [3] poor results in Phase IIb trials led to it being discontinued from development for treatment of RSV. [4] Research continues to determine whether it may be useful for the treatment of diseases caused by other RNA viruses, and it has been found to show activity against Nipah virus. [5]

See also

References

  1. ↑ Wang G, Deval J, Hong J, Dyatkina N, Prhavc M, Taylor J, Fung A, Jin Z, Stevens SK, Serebryany V, Liu J, Zhang Q, Tam Y, Chanda SM, Smith DB, Symons JA, Blatt LM, Beigelman L (February 2015). "Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection". Journal of Medicinal Chemistry. 58 (4): 1862–78. doi:10.1021/jm5017279. PMID   25667954.
  2. ↑ Brendish NJ, Clark TW (December 2017). "Antiviral treatment of severe non-influenza respiratory virus infection". Current Opinion in Infectious Diseases. 30 (6): 573–578. doi:10.1097/QCO.0000000000000410. PMID   29095723. S2CID   2662061.
  3. ↑ Patel K, Kirkpatrick CM, Nieforth KA, Chanda S, Zhang Q, McClure M, Fry J, Symons JA, Blatt LM, Beigelman L, DeVincenzo JP, Huntjens DR, Smith PF (February 2019). "Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans". The Journal of Antimicrobial Chemotherapy. 74 (2): 442–452. doi: 10.1093/jac/dky415 . PMID   30376079.
  4. ↑ Taylor P (18 October 2018). "Johnson & Johnson takes $630M hit on RSV drug bought with Alios". fiercebiotech.com.
  5. ↑ Lo MK, Amblard F, Flint M, Chatterjee P, Kasthuri M, Li C, Russell O, Verma K, Bassit L, Schinazi RF, Nichol ST, Spiropoulou CF (January 2020). "Potent in vitro activity of β-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus". Antiviral Research. 175 104712. doi:10.1016/j.antiviral.2020.104712. PMC   7054849 . PMID   31935422.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.